Taken together, results from the current study determines newly characterized constipation phenotypes in ICR mice orally administrated MP for 2 weeks, including a decrease in stool parameters, delay of gastrointestinal transit, alteration of the histopathological structure of the mid colon, and suppression of mucin. The gene discussed is MUC5AC; the disease is constipation disorder.